Hicara: China’s home-grown CD19 CAR-T cell therapy approved for lymphoma
31/07/2025
HICARA, developed by Hrain Bio, becomes China’s first home-grown CD19 CAR-T cell therapy approved for relapsed or refractory large B-cell lymphoma, marking a major milestone in Chinese immunotherapy innovation.